Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma
An analysis of skin cancers reported to the FDA Adverse Event Reporting System (FAERS) has revealed the need for close skin cancer monitoring in patients receiving certain multiple sclerosis (MS) therapies, including the drugs Gilenya, Lemtrada, Mayzent, and Ocrevus. In particular, the findings showed the MS drugs Gilenya and Ocrevus linked to melanoma, with Gilenya linked to squamous cell carcinoma and basal cell carcinoma, also.
These findings come from a research study reported in this recent article, "S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal", published by the medical journal Multiple Sclerosis and Related Disorders.
From the Abstract for this March 2022 medical journal article, in its Introduction section, we get the following:
[Sphingosine 1-phosphate (S1P)] receptor modulators are oral Disease-Modifying Therapies (DMTs) for Multiple Sclerosis, which were associated with cases of basal cell carcinoma in clinical trials. This study aims at investigating in a real-world adverse event reporting system whether S1P receptor modulators increase the risk of skin cancer reporting, compared to other DMTs.
Strictly Confidential, No Obligation.
For more details, from the full-text Conclusion part of this new medical research article:
The present study detected a potential safety signal for the S1P receptor modulators [Gilenya (fingolimod)] and [Mayzent (siponimod)] for basal cell carcinomas. [Gilenya (fingolimod)] had also an increased signal of disproportionate reporting for melanoma and squamous cell carcinoma. [Lemtrada (alemtuzumab)] presented also a signal for all three types of skin cancer, while [Ocrevus (ocrelizumab)] presented a potential safety signal for melanoma.... These findings -- especially the potential signals for melanoma -- need to be further evaluated, including more substantial evidence from other real-world prospective trials. Based on the current evidence and taken the rapid development of new orally administered S1P receptor modulators, such as Ozanimod and Ponesimod into consideration, monitoring measures such as skin examination at baseline to screen for precancerous skin lesions or additional risk factors, regular dermatologic examinations, and patient's education for regular self-skin controls seem indicated for MS patients under treatment with S1P receptor modulators.
For some explanation of this MS drugs adverse reactions research study, we refer you to a Multiple Sclerosis News Today article, "More Skin Cancer Reported to FDA From Patients on Certain Oral DMTs". This news report points out these two important facts:
- The findings showed the MS drugs Gilenya and Ocrevus linked to melanoma skin cancer: and,
- The findings showed Gilenya linked to squamous cell carcinoma and basal cell carcinoma, also.
We will continue to monitor the safety profile of Gilenya and Ocrevus, as well as Lemtrada and Mayzent, with a focus on the possible increased risks of these three skin cancers: melanoma; squamous cell carcinoma; and, basal cell carcinoma.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)